17 beta-Estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate.
To compare the metabolic effects of two different administration routes of estrogen associated with cyproterone acetate (CPA) in young women. Randomized and prospective study. University medical and research center. Sixty-five premenopausal young women with clinical hyperandrogenism. A high dose of CPA was administered, associated with either transdermal (group T) or oral (group O) 17 beta-E2. Glucose tolerance, plasma lipid level, coagulation and fibrinolysis parameters, and angiotensinogen, before and at 6 and 12 months during treatment. At 12 months, fasting blood glucose and basal insulin levels were significantly lower in group O than in group T. The increase in angiotensinogen was greater in group O, however, without modification in arterial blood pressure. No significant difference between the two groups was observed in lipids, coagulation, and fibrinolysis. Natural estrogens associated with CPA have no patent deleterious metabolic effect. However, the choice of oral estrogen administration seems to be better among patients with disorders such as hyperandrogenism or obesity with potential hyperinsulinism.